01.08.1998 | ORIGINAL ARTICLE
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting
Pooled analysis of 14 clinical trials
Erschienen in: Supportive Care in Cancer | Ausgabe 5/1998
Einloggen, um Zugang zu erhalten